Breaking News, Collaborations & Alliances

Kineta, Genentech Enter Collaboration

To develop Kineta's α9/α10 nicotinic acetylcholine receptor (nAChR) antagonists for the treatment of chronic pain

Kineta Chronic Pain, a subsidiary of Kineta, Inc., has entered into an exclusive option and license agreement with Genentech, a member of the Roche Group, to develop Kineta’s α9/α10 nicotinic acetylcholine receptor (nAChR) antagonists for the treatment of chronic pain.     The α9/α10 nAChR is a novel target for the treatment of chronic neuropathic pain. Preclinical data showed investigational compounds that specifically target the receptor reduced pain behaviors in animal models an...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters